Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Arsenic Trioxide Suppresses Growth of BCR-ABL1 Positive Cells with "Gatekeeper" or Compound Mutation

Afsar Ali Mian, Hadiqa Raees, Sujjawal Ahmad, Oliver Ottmann, El-Nasir M A Lalani

Blood (2021) 138 (Supplement 1): 4346.

https://doi.org/10.1182/blood-2021-154511

Published: 2021

Journal Articles

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Afsar Ali Mian, BSc, MPhil, PhD, Usva Zafar, BSc, Oliver Ottmann, Prof, MD, Martin Ruthardt, MD, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA

Blood (2019) 134 (Supplement_1): 2570.

https://doi.org/10.1182/blood-2019-130898

Published: 2019

Journal Articles

The ''Gatekeeper'' Mutation T315I in BCR/ABL Confers Additional Oncogenic Activities to Philadelphia Chromosome Positive Leukemia

Usva Zafar, BSc, Mohammed Yusuf, PhD, Rikhia Chakraborty, PhD, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA, Afsar Ali Mian, BSc, MPhil, PhD

Blood (2019) 134 (Supplement_1): 5196.

https://doi.org/10.1182/blood-2019-131694

Published: 2019

Journal Articles

CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells

Mateusz Legut, Garry Dolton, Afsar Ali Mian, Oliver G. Ottmann, Andrew K. Sewell

Blood (2018) 131 (3): 311–322.

https://doi.org/10.1182/blood-2017-05-787598

Published: 2018

Includes: Supplemental data

Journal Articles

T(15;17)-PML/RAR-Induced Leukemogenesis: Long-Term Repopulating Hematopoietic Stem Cells as the Initial Target and More Mature Progenitors as the Potential Targets for Final Leukemic Transformation.

Claudia Oancea, Brigitte Rüster, PhD, Jessica Roos, Afsar Ali Mian, Tatjana Micheilis, Hannelore Held, Anjali Dubey, Hubert Serve, Reinhard Henschler, Martin Ruthardt

Blood (2009) 114 (22): 3980.

https://doi.org/10.1182/blood.V114.22.3980.3980

Published: 2009

Journal Articles

Oligomerization Inhibition Combined with Allosteric Inhibition Abrogates the Transformation Potential of T315I-Positive BCR/ABL.

Afsar Ali Mian, Claudia Oancea, Zihan Zhao, Hubert Serve, MD, PhD, Ottmann Oliver, Martin Ruthardt, MD

Blood (2009) 114 (22): 2964.

https://doi.org/10.1182/blood.V114.22.2964.2964

Published: 2009

NARROW

Arsenic Trioxide Suppresses Growth of BCR-ABL1 Positive Cells with "Gatekeeper" or Compound Mutation

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

The ''Gatekeeper'' Mutation T315I in BCR/ABL Confers Additional Oncogenic Activities to Philadelphia Chromosome Positive Leukemia

CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells

T(15;17)-PML/RAR-Induced Leukemogenesis: Long-Term Repopulating Hematopoietic Stem Cells as the Initial Target and More Mature Progenitors as the Potential Targets for Final Leukemic Transformation.

Oligomerization Inhibition Combined with Allosteric Inhibition Abrogates the Transformation Potential of T315I-Positive BCR/ABL.

Email alerts

ASH Publications

American Society of Hematology

Arsenic Trioxide Suppresses Growth of BCR-ABL1 Positive Cells with "Gatekeeper" or Compound Mutation

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

The ''Gatekeeper'' Mutation T315I in BCR/ABL Confers Additional Oncogenic Activities to Philadelphia Chromosome Positive Leukemia

CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells

T(15;17)-PML/RAR-Induced Leukemogenesis: Long-Term Repopulating Hematopoietic Stem Cells as the Initial Target and More Mature Progenitors as the Potential Targets for Final Leukemic Transformation.

Oligomerization Inhibition Combined with Allosteric Inhibition Abrogates the Transformation Potential of T315I-Positive BCR/ABL.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only